PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Top Ranked Growth Stocks to Buy for November 4th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 4th.
Here's Why Momentum Investors Will Love PerkinElmer (PKI)
by Zacks Equity Research
Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.
PerkinElmer (PKI) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results benefit from growth in Diagnostics segment. However, forex remains a woe.
Should You Buy PerkinElmer (PKI) Ahead of Earnings?
by Zacks Equity Research
PerkinElmer (PKI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is PerkinElmer (PKI) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (PKI) Outperforming Other Computer and Technology Stocks This Year?
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at Diagnostics segment.
PerkinElmer (PKI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co
Bet on These 5 Top-Ranked Stocks With Strong Sales Growth
by Swayta Shah
Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.
Badger Meter (BMI) Q3 Earnings Top Estimates, Shares Gain
by Zacks Equity Research
Despite COVID-19 uncertainties, Badger Meter (BMI) witnesses solid third-quarter 2020 results with major rise in both top and bottom lines on the back of consistent demand across most end markets.
PerkinElmer (PKI) Is Up 4.11% in One Week: What You Should Know
by Zacks Equity Research
Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why PerkinElmer (PKI) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons Why Growth Investors Shouldn't Overlook PerkinElmer (PKI)
by Zacks Equity Research
PerkinElmer (PKI) possesses solid growth attributes, which could help it handily outperform the market.
Is PerkinElmer (PKI) Stock Outpacing Its Computer and Technology Peers This Year?
by Zacks Equity Research
Is (PKI) Outperforming Other Computer and Technology Stocks This Year?
Baxter's Clinimix and Clinimix E Injections Receive FDA Nod
by Zacks Equity Research
Baxter's (BAX) Clinimix and Clinimix E with Higher Protein Injection received FDA approval, which will help clinicians to improve care for critically ill patients.
Here's Why You Should Avoid Betting on Intuitive Surgical Now
by Zacks Equity Research
Intense competition in the global MedTech space and weak operational performance weighs on Intuitive Surgical (ISRG).
Veeva's Offering Chosen by Idorsia to Drive Digital Engagement
by Zacks Equity Research
Veeva Systems' (VEEV) Commercial Cloud selected by Idorsia to enhance its digital field force in the United States, Japan and countries across Europe.
Zacks.com featured highlights include: PKI, KLAC, TRU, UGI and TKR
by Zacks Equity Research
Zacks.com featured highlights include: PKI, KLAC, TRU, UGI and TKR
PRA Health (PRAH) Enters Into Strategic Deal With Deep Lens
by Zacks Equity Research
PRA Health's (PRAH) deal with Deep Lens can help detect and match oncology patients to suitable clinical trials and best precision therapies.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
5 Stocks With Attractive Sales Growth to Invest in Now
by Swayta Shah
Solid sales growth is a major characteristic of potential winners. The firms that put more emphasis on sales management have a competitive advantage, as strong sales usually get converted into growth.
Is PerkinElmer (PKI) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (PKI) Outperforming Other Computer and Technology Stocks This Year?
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP.
Varian (VAR) Expands Presence With Germany's Ethos Order
by Zacks Equity Research
Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.